Shilpa Medicare Limited (NSE:SHILPAMED) disclosed the outcome of its board meeting held on 5 August 2026, approving unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, alongside several key corporate decisions including a EUR 7 million investment plan and the 39th AGM date.
Key Highlights
- Consolidated revenue from operations for Q1 FY27 stood at Rs 46,578 lakhs, up from Rs 32,147 lakhs in Q1 FY26, with consolidated net profit attributable to parent company owners at Rs 10,088 lakhs against Rs 4,688 lakhs a year earlier.
- Standalone net profit for the quarter ended 30 June 2026 was Rs 6,492 lakhs, compared with Rs 1,871 lakhs in the corresponding quarter of the previous year, with basic and diluted EPS of Rs 3.32 (not annualised).
- The board confirmed a proposed investment of up to EUR 7 million by wholly owned subsidiary Shilpa Biocare Private Limited in Gate2Brain, to be made through cash infusion, equity for services, or project development in a fungible manner.
- The record date for determining shareholders eligible for the proposed final dividend for FY2025-26, if declared at the 39th AGM on 11 September 2026, is set as Friday, 4 September 2026.
About the Company
Shilpa Medicare Limited (NSE:SHILPAMED), headquartered in Raichur, Karnataka, is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs), finished dosage formulations, and biologics. Its material subsidiary, Shilpa Biologicals Ltd, focuses on biologics. The company exports to regulated markets across the US, Europe, and other geographies.
Announcement in Detail
The board meeting, held on 5 August 2026 from 11:55 a.m. to 1:45 p.m., approved unaudited standalone and consolidated financial results for Q1 FY27 (quarter ended 30 June 2026), reviewed by the Audit Committee and subject to a limited review by statutory auditors with an unmodified opinion. Standalone total income was Rs 19,860 lakhs versus Rs 10,648 lakhs in Q1 FY26, while consolidated total income reached Rs 46,891 lakhs against Rs 32,785 lakhs in Q1 FY26.
The board also approved the appointment of Mr. Sharath Reddy Kalakota (DIN: 03603460) as Whole Time Director, subject to shareholder approval at the AGM. Additionally, it approved commission of up to 1% of net profits of Shilpa Biologicals Ltd to Mr. Madhav Vishnukant Bhutada (DIN: 08222055), Non-Executive Director of SBPL, effective 1 April 2026. The 39th AGM is scheduled for 11 September 2026 via video conferencing, with e-voting running from 7 September to 10 September 2026.
Impact on Investors
Investors will note that the consolidated net profit attributable to parent company owners more than doubled year-on-year to Rs 10,088 lakhs in Q1 FY27 from Rs 4,688 lakhs, based on the unaudited figures disclosed. The standalone results also show a significant improvement, with profit rising from Rs 1,871 lakhs to Rs 6,492 lakhs over the same period.
The filing shows the proposed final dividend for FY2025-26, if approved by shareholders at the 39th AGM, will be paid to shareholders on record as of 4 September 2026. The EUR 7 million investment in Gate2Brain through subsidiary Shilpa Biocare Private Limited remains subject to the combination structure described and does not yet have full regulatory or shareholder approval confirmed in this filing. Shareholders will observe that the director appointment of Mr. Kalakota is also pending AGM approval.
Sector / Market Context
India's pharmaceutical industry is among the largest globally by volume, with API manufacturing forming a significant export base. According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India's pharma exports have been broadly expanding year-on-year, providing a backdrop against which Shilpa Medicare's year-on-year consolidated revenue growth from Rs 32,147 lakhs to Rs 46,578 lakhs in Q1 can be contextualised.